Norges Bank’s Ambrx Biopharma Inc AMAM Stock Holding History

Norges Bank’s Portfolio AMAM Stock Details AMAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-62,396	Closed	-$165K	–	2143
2022 Q2	$165K	Sell	62,396 -7,604	-11%	-$29K	﹤0.01%	2040
2022 Q1	$288K	Hold	70,000	–	–	﹤0.01%	2125
2021 Q4	$632K	Hold	70,000	–	–	﹤0.01%	2135
2021 Q3	$945K	Hold	70,000	–	–	﹤0.01%	2151
2021 Q2	$1.37M	Buy	+70,000	New	+$1.19M	﹤0.01%	2066

Other funds holding AMAM

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Fosun International Hong Kong, China $399M AUM 16.11% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Norges Bank's AMAM Position: Q3 2022 in Review

Norges Bank sold out of Ambrx Biopharma Inc (AMAM) in Q3 2022, closing a stake of 62,396 shares — an estimated $165K sold.

Norges Bank first reported a position in AMAM in Q2 2021 and held it in 5 quarters. The position peaked at $1.37M in Q2 2021. 16 funds tracked by Wall St. Rank hold AMAM as of Q3 2022.

Norges Bank reported no remaining Ambrx Biopharma Inc position as of Q3 2022 after selling out during the quarter.
Norges Bank sold 62,396 Ambrx Biopharma Inc shares in Q3 2022, an estimated $165K.
Norges Bank first reported a position in Ambrx Biopharma Inc in Q2 2021 and held it in 5 quarters.
Norges Bank's Ambrx Biopharma Inc position peaked at $1.37M in Q2 2021.
16 funds tracked by Wall St. Rank held Ambrx Biopharma Inc as of Q3 2022.

Based on Norges Bank's 13F filing for Q3 2022, filed 14 Nov 2022.